Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 02, 2002. The report details corporate actions regarding share re-purchases and updates on directors' interests in company shares and employee benefit trusts.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to a share re-purchase transaction:
- Shares Purchased: 800,000 ordinary shares.
- Purchase Price: 1,242.2382p per share.
- Transaction Date: November 27, 2002.
Material Changes
The primary material change reported is the reduction of the company's share capital through the purchase and cancellation of 800,000 ordinary shares. Additionally, there were movements in employee benefit trusts and director share options:
- Share Option Grant: Director J.D. Coombe was granted options over 1,031 ordinary shares at a price of £9.16 per share under the Savings Related Share Option Scheme.
- Trust Transfers: The SmithKline Beecham Employee Benefit Trust transferred 79,524 shares to the 1991 Share Option Plan and 998 shares to the UK Bonus Investment Plan.
- ADR Movement: The GlaxoSmithKline US Retirement Savings Plan increased its holding of Ordinary Share ADRs from 18,172,040 to 18,199,075 at an average price of $38.40.
- Verify the total number of shares authorized for re-purchase under the May 20, 2002 shareholder resolution to assess remaining capacity.
- Confirm the impact of the 800,000 share cancellation on the company's total outstanding share count and earnings per share.
- Review the full terms of the SmithKline Beecham Employee Benefit Trust and US Retirement Savings Plan to understand the scope of director interests.
- Check subsequent filings for any further share buyback activity or changes in director holdings.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, specific risks, contingencies, or unusual items beyond the routine corporate actions described above.